BostonGene, a Waltham, MA-based personalized medicine company, closed a $150m Series B funding.
NEC Corporation (NEC; TSE: 6701) led the financing with participation from Impact Investment Capital and Japan Industrial Partners.
The company intends to use the capital to scale growth, including continued innovation, clinical and research partnerships, and international expansion. Further, leveraging NEC’s infrastructure, BostonGene and NEC intend to form a joint venture to bring lifesaving solutions to patients in Japan and other Asian countries.
Led by Andrew Feinberg, President, and CEO, BostonGene provides an innovative computational platform that performs AI-based molecular and immune profiling to discover correlations between tumor genomics, a patient’s immune system, and the effectiveness of all available approved and investigational treatments. The BostonGene Tumor Portrait™ Tests, a sophisticated analysis of the tumor and tumor microenvironment (TME), reveals critical drivers of each tumor, including immune microenvironment properties, actionable mutations, and biomarkers of response to diverse therapies, and recommended therapies. BostonGene’s integrated model of tumor genetics, transcriptomics, microenvironment, and tumor composition provides a 360° overview of a patient tumor to give physicians invaluable insights into potential treatment options.